Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:VERA News 11 December 2025 - 30 December 2025

Vera Therapeutics stock drops 3% today as biotech slips into year-end trading

Vera Therapeutics stock drops 3% today as biotech slips into year-end trading

NEW YORK, December 30, 2025, 2:26 PM ET — Regular session Vera Therapeutics, Inc. shares slid 3.4% to $50.45 in afternoon trading on Tuesday, giving back some recent gains as biotech stocks softened late in the year. The move matters now because Vera has become a bellwether “event-driven” biotech name, where day-to-day trading can swing sharply as investors calibrate risk around FDA timelines and competitive positioning in kidney disease. Thin year-end liquidity can amplify those swings, and traders have been quick to trim exposure to smaller, higher-beta healthcare names when the sector loses momentum. Minutes from the Federal Reserve’s December
30 December 2025
··
Vera Therapeutics (VERA) Stock Dips in Thin Post‑Christmas Trading as Wall Street Weighs FDA Filing, $300M Raise, and IgA Nephropathy Competition

Vera Therapeutics (VERA) Stock Dips in Thin Post‑Christmas Trading as Wall Street Weighs FDA Filing, $300M Raise, and IgA Nephropathy Competition

Friday, December 26, 2025, 11:17 a.m. ET in New York. In that context—a quiet, low‑liquidity post‑Christmas session with major U.S. indexes hovering near record highs—Vera Therapeutics, Inc. (Nasdaq: VERA) is trading lower midday. Reuters and the AP both describe today’s market as subdued, with institutions largely “checked out” for year‑end and the broader tape moving only slightly. Reuters As of the latest available quote in this session, VERA is at about $54.24, down ~2.6% on the day, with a day range roughly $54.05–$55.30 and notably light volume—exactly the kind of trading environment where single‑stock moves can look louder than the
26 December 2025
Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets

Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets

Vera Therapeutics, Inc. (NASDAQ: VERA) is back center stage on December 11, 2025, as traders digest a fresh equity offering, strong late‑stage clinical data, and a newly filed Biologics License Application (BLA) for its lead drug, atacicept, in IgA nephropathy (IgAN). During Thursday’s session, VERA shares were trading around $46, up roughly 3–4% on the day and near 52‑week highs, leaving the company with a market capitalization of about $2.9–3.0 billion.Stock Titan Below is a full rundown of the latest news, forecasts, and analysis as of December 11, 2025. Vera Therapeutics stock today: price action and technical backdrop VERA has
11 December 2025
·

Stock Market Today

Financial services stocks rally as XLF jumps, Dow hits 50,000 — what to watch next week

Financial services stocks rally as XLF jumps, Dow hits 50,000 — what to watch next week

7 February 2026
U.S. financial stocks rose Friday, with the XLF fund up 1.8% and the Dow closing above 50,000 for the first time, gaining 2.47%. Goldman Sachs jumped 4.3%, JPMorgan 3.9%, and Citigroup 6.0%. The Federal Reserve held rates steady, and San Francisco Fed President Mary Daly signaled possible cuts this year. Investors await January jobs and inflation data next week.
Data Center Stocks Surge Into the Weekend: Digital Realty, Equinix and Vertiv Set Up a Big Week Ahead

Data Center Stocks Surge Into the Weekend: Digital Realty, Equinix and Vertiv Set Up a Big Week Ahead

7 February 2026
Digital Realty, Equinix, and Vertiv shares surged Friday, with Vertiv up 10% and Digital Realty rising 4.1%, as investors rotated back into AI-linked data center stocks. The move followed Amazon’s $200 billion and Alphabet’s $175–185 billion 2026 capex targets. Digital Realty set 2026 core FFO guidance at $7.90 to $8.00 per share. Wall Street ended the week broadly higher, led by chipmakers.
Go toTop